Adavosertib
Adavosertib is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the kinase enzyme WEE1. It is being developed by AstraZeneca. It is being investigated as a treatment for pancreatic cancer with a phase 1 trial, and ovarian cancer, in combination with another anti-cancer drug, gemcitabine, as a phase 2 trial.